Importantly, we demonstrate for the first time that CCDC50 expression serves as a reliable diagnostic marker for distinguishing BPDCN from AML in diagnostically challenging cases, as well as an effective biomarker for disease monitoring. Here, CCDC50 is linked to acute myeloid leukemia.